GBA-associated PD: chances and obstacles for targeted treatment strategies

Publikation: Beitrag in FachzeitschriftÜbersichtsartikel (Review)EingeladenBegutachtung

Beitragende

  • Günter Höglinger - , Medizinische Hochschule Hannover (MHH) (Autor:in)
  • Claudia Schulte - , Universitätsklinikum Tübingen (Autor:in)
  • Wolfgang H Jost - , Parkinson-Klinik Ortenau (Autor:in)
  • Alexander Storch - , Universität Rostock (Autor:in)
  • Dirk Woitalla - , St. Josef Krankenhaus GmbH Moers (Autor:in)
  • Rejko Krüger - , Luxembourg Institute of Health (Autor:in)
  • Björn Falkenburger - , Klinik und Poliklinik für Neurologie (Autor:in)
  • Kathrin Brockmann - , Universitätsklinikum Tübingen (Autor:in)

Abstract

Given the clear role of GBA in the pathogenesis of Parkinson's disease (PD) and its impact on phenotypical characteristics, this review provides an overview of the current knowledge of GBA-associated PD with a special focus on clinical trajectories and the underlying pathological mechanisms. Importantly, differences and characteristics based on mutation severity are recognized, and current as well as potential future treatment options are discussed. These findings will inform future strategies for patient stratification and cohort enrichment as well as suitable outcome measures when designing clinical trials.

Details

OriginalspracheEnglisch
Seiten (von - bis)1219-1233
Seitenumfang15
FachzeitschriftJournal of neural transmission
Jahrgang129
Ausgabenummer9
PublikationsstatusVeröffentlicht - Sept. 2022
Peer-Review-StatusJa

Externe IDs

PubMedCentral PMC9463270
Scopus 85131102002
ORCID /0000-0002-2387-526X/work/150328949

Schlagworte

Schlagwörter

  • Cohort Studies, Glucosylceramidase/genetics, Humans, Mutation, Parkinson Disease/drug therapy

Bibliotheksschlagworte